{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:53:28Z","timestamp":1794243208114,"version":"4.9.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Clinical Key Specialty Construction Program","award":["2021"],"award-info":[{"award-number":["2021"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072986"],"award-info":[{"award-number":["82072986"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major Research Projects for Young and Middle-aged Researchers of Fujian Provincial Health Commission","award":["2021ZQNZD010"],"award-info":[{"award-number":["2021ZQNZD010"]}]},{"name":"Science and Technology Pilot Program of Fujian Province, China","award":["2021Y0053"],"award-info":[{"award-number":["2021Y0053"]}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian province","award":["2021Y9196"],"award-info":[{"award-number":["2021Y9196"]}]},{"name":"High-level Talent Training Program of Fujian Cancer Hospital","award":["2022YNG07"],"award-info":[{"award-number":["2022YNG07"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian province","doi-asserted-by":"crossref","award":["2023J01121763"],"award-info":[{"award-number":["2023J01121763"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75396-z","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T12:03:43Z","timestamp":1729253023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based on pre-treatment plasma EBV DNA"],"prefix":"10.1038","volume":"14","author":[{"given":"Youliang","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunqin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"issue":"11","key":"75396_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong, K. C. W. et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat. Rev. Clin. Oncol. 18 (11), 679\u2013695 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"75396_CR2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/annonc\/mdz231","volume":"30","author":"MF Ji","year":"2019","unstructured":"Ji, M. F. et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann. Oncol. 30 (10), 1630\u20131637 (2019).","journal-title":"Ann. Oncol."},{"issue":"3","key":"75396_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.4143\/crt.2020.899","volume":"53","author":"JJ Yao","year":"2021","unstructured":"Yao, J. J. et al. Development and validation of web-based nomograms to precisely predict survival outcomes of non-metastatic Nasopharyngeal Carcinoma in an endemic area. Cancer Res. Treat. 53 (3), 657\u2013670 (2021).","journal-title":"Cancer Res. Treat."},{"key":"75396_CR4","doi-asserted-by":"crossref","unstructured":"AlSarraf, M. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J. Clin. Oncol. 16(4), 1310-1317 (1998).","DOI":"10.1200\/JCO.1998.16.4.1310"},{"key":"75396_CR5","doi-asserted-by":"crossref","unstructured":"Xu, M. et al. Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study. BMJ Open. 11(8), e045417 (2021).","DOI":"10.1136\/bmjopen-2020-045417"},{"key":"75396_CR6","doi-asserted-by":"crossref","unstructured":"Huang, H. et al. Immunotherapy for nasopharyngeal carcinoma: current status and prospects (review). Int. J. Oncol. 63(2), 97 (2023).","DOI":"10.3892\/ijo.2023.5545"},{"key":"75396_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","volume":"119","author":"Q Yang","year":"2019","unstructured":"Yang, Q. et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur. J. Cancer. 119, 87\u201396 (2019).","journal-title":"Eur. J. Cancer"},{"issue":"22","key":"75396_CR8","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.22.00327","volume":"40","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Final overall survival analysis of Gemcitabine and Cisplatin Induction Chemotherapy in nasopharyngeal carcinoma: a Multicenter, Randomized Phase III Trial. J. Clin. Oncol. 40 (22), 2420\u20132425 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"75396_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.32099","volume":"145","author":"WF Li","year":"2019","unstructured":"Li, W. F. et al. Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int. J. Cancer. 145 (1), 295\u2013305 (2019).","journal-title":"Int. J. Cancer"},{"key":"75396_CR10","doi-asserted-by":"crossref","unstructured":"Mao, Y. P. et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chin. J. Cancer. 35(1), 103 (2016).","DOI":"10.1186\/s40880-016-0167-2"},{"issue":"7","key":"75396_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.6004\/jnccn.2017.0121","volume":"15","author":"LL Tang","year":"2017","unstructured":"Tang, L. L. et al. Validation of the 8th Edition of the UICC\/AJCC staging system for Nasopharyngeal Carcinoma from Endemic Areas in the intensity-modulated Radiotherapy Era. J. Natl. Compr. Canc. Netw. 15 (7), 913\u2013919 (2017).","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"4","key":"75396_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","volume":"127","author":"G Gupta","year":"2006","unstructured":"Gupta, G. & Massagu\u00e9, J. Cancer metastasis: building a framework. Cell. 127 (4), 679\u2013695 (2006).","journal-title":"Cell"},{"key":"75396_CR13","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. The efficacy and toxicities of intensive induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with N3 disease. Sci. Rep. 7(1), 3668 (2017).","DOI":"10.1038\/s41598-017-03963-8"},{"key":"75396_CR14","doi-asserted-by":"crossref","unstructured":"Wang, F. et al. Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma. Medicine. 99(39), e22283 (2020).","DOI":"10.1097\/MD.0000000000022283"},{"issue":"10","key":"75396_CR15","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/hed.20066","volume":"26","author":"WI Wei","year":"2004","unstructured":"Wei, W. I. et al. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study. Head Neck. 26 (10), 878\u2013883 (2004).","journal-title":"Head Neck"},{"issue":"24","key":"75396_CR16","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","volume":"350","author":"JC Lin","year":"2004","unstructured":"Lin, J. C. et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl. J. Med. 350 (24), 2461\u20132470 (2004).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"75396_CR17","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1186\/s12885-018-5177-9","volume":"18","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma. BMC Cancer. 18 (1), 1276 (2018).","journal-title":"BMC Cancer"},{"issue":"3","key":"75396_CR18","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/cam4.3669","volume":"10","author":"W Li","year":"2020","unstructured":"Li, W. et al. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma. Cancer Med. 10 (3), 883\u2013894 (2020).","journal-title":"Cancer Med."},{"issue":"1","key":"75396_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12885-020-6555-7","volume":"20","author":"SL Liu","year":"2020","unstructured":"Liu, S. L. et al. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level. BMC Cancer. 20 (1), 89 (2020).","journal-title":"BMC Cancer"},{"issue":"6","key":"75396_CR20","first-page":"4059","volume":"24","author":"JY Shao","year":"2004","unstructured":"Shao, J. Y. et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res. 24 (6), 4059\u20134066 (2004).","journal-title":"Anticancer Res."},{"key":"75396_CR21","doi-asserted-by":"crossref","unstructured":"Li, Y. et al. Prognostic model on overall survival in elderly nasopharyngeal carcinoma patients: a recursive partitioning analysis identifying pre-treatment risk stratification. Radiat. Oncol.  18(1), 104 (2023).","DOI":"10.1186\/s13014-023-02272-x"},{"key":"75396_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","volume":"153","author":"AWM Lee","year":"2021","unstructured":"Lee, A. W. M. et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur. J. Cancer. 153, 109\u2013122 (2021).","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"75396_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan, K. C. A. et al. Analysis of plasma Epstein\u2013Barr Virus DNA to screen for nasopharyngeal Cancer. N. Engl. J. Med. 377 (6), 513\u2013522 (2017).","journal-title":"N. Engl. J. Med."},{"key":"75396_CR24","doi-asserted-by":"crossref","unstructured":"Rotolo, F. et al. Surrogate end points for overall survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: an individual Patient Data Meta-analysis. J. Natl. Cancer Inst. 109(4), djw239 (2017).","DOI":"10.1093\/jnci\/djw239"},{"issue":"11","key":"75396_CR25","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun, Y. et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 17 (11), 1509\u20131520 (2016).","journal-title":"Lancet Oncol."},{"key":"75396_CR26","unstructured":"Zhang, Y. et al. Gemcitabine and Cisplatin Induction Chemotherapy in nasopharyngeal carcinoma. N. Engl. J. Med. 381(12), 1124-1135 (2019)."},{"key":"75396_CR27","doi-asserted-by":"crossref","unstructured":"Ng, W. T. et al. Current management of stage IV nasopharyngeal carcinoma without distant metastasis. Cancer Treat. Rev. 85, 101995 (2020).","DOI":"10.1016\/j.ctrv.2020.101995"},{"key":"75396_CR28","doi-asserted-by":"crossref","unstructured":"Niu, X. et al. Long-term outcomes of induction chemotherapy followed by intensity-modulated radiotherapy and adjuvant chemotherapy in nasopharyngeal carcinoma patients with N3 disease. Translational Oncol. 14(12), 101216 (2021).","DOI":"10.1016\/j.tranon.2021.101216"},{"issue":"12","key":"75396_CR29","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1002\/hed.25955","volume":"41","author":"JE Han","year":"2019","unstructured":"Han, J. E. et al. Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease. Head Neck. 41 (12), 4076\u20134087 (2019).","journal-title":"Head Neck"},{"key":"75396_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.oraloncology.2016.10.014","volume":"62","author":"H Peng","year":"2016","unstructured":"Peng, H. et al. Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a propensity score matching analysis. Oral Oncol. 62, 78\u201384 (2016).","journal-title":"Oral Oncol."},{"issue":"1","key":"75396_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21147\/j.issn.1000-9604.2018.01.06","volume":"30","author":"J Wei","year":"2018","unstructured":"Wei, J. et al. Cycle number of neoadjuvant chemotherapy might influence survival of patients with T1-4N2-3M0 nasopharyngeal carcinoma. Chin. J. Cancer Res. 30 (1), 51\u201360 (2018).","journal-title":"Chin. J. Cancer Res."},{"key":"75396_CR32","doi-asserted-by":"crossref","unstructured":"Pingping, J. et al. Nutritional status and its correlation to prognosis of nasopharyngeal carcinoma patients in different ages in China: a multicenter cohort study. Support Care Cancer. 31(12), 638 (2023).","DOI":"10.1007\/s00520-023-08104-8"},{"issue":"1","key":"75396_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12935-021-01862-7","volume":"21","author":"W Liu","year":"2021","unstructured":"Liu, W. et al. The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis. Cancer Cell. Int. 21 (1), 164 (2021).","journal-title":"Cancer Cell. Int."},{"issue":"4","key":"75396_CR34","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1002\/cam4.5256","volume":"12","author":"YT Jiang","year":"2022","unstructured":"Jiang, Y. T. et al. Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response. Cancer Med. 12 (4), 4010\u20134022 (2022).","journal-title":"Cancer Med."},{"key":"75396_CR35","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.2147\/CMAR.S377731","volume":"14","author":"YT Jiang","year":"2022","unstructured":"Jiang, Y. T. et al. A Nomogram to identify the optimal candidates for induction chemotherapy in Advanced N-Stage Nasopharyngeal Carcinoma. Cancer Manage. Res. 14, 2583\u20132596 (2022).","journal-title":"Cancer Manage. Res."},{"issue":"1","key":"75396_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cncr.31741","volume":"125","author":"R Guo","year":"2018","unstructured":"Guo, R. et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein\u2010Barr virus\u2010related nasopharyngeal carcinoma. Cancer. 125 (1), 79\u201389 (2018).","journal-title":"Cancer"},{"issue":"11","key":"75396_CR37","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JCO.21.01467","volume":"40","author":"XY Li","year":"2022","unstructured":"Li, X. Y. et al. Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-Selected low-risk Locoregionally Advanced Nasopharyngeal Carcinoma: a phase II randomized Noninferiority Trial. J. Clin. Oncol. 40 (11), 1163\u20131173 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"75396_CR38","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.ejca.2013.03.008","volume":"49","author":"XB Wan","year":"2013","unstructured":"Wan, X. B. et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur. J. Cancer. 49 (10), 2356\u20132364 (2013).","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"75396_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.4143\/crt.2017.180","volume":"50","author":"QY Chen","year":"2018","unstructured":"Chen, Q. Y. et al. Pretreatment serum amyloid A and C-reactive protein comparing with Epstein-Barr Virus DNA as prognostic indicators in patients with nasopharyngeal carcinoma: a prospective study. Cancer Res. Treat. 50 (3), 701\u2013711 (2018).","journal-title":"Cancer Res. Treat."},{"issue":"3","key":"75396_CR40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.radonc.2012.09.001","volume":"104","author":"R Guo","year":"2012","unstructured":"Guo, R. et al. Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiotherapy Oncology: J. Eur. Soc. Therapeutic Radiol. Oncol. 104 (3), 294\u2013299 (2012).","journal-title":"Radiotherapy Oncology: J. Eur. Soc. Therapeutic Radiol. Oncol."},{"issue":"6","key":"75396_CR41","doi-asserted-by":"publisher","first-page":"664","DOI":"10.7150\/jca.14183","volume":"7","author":"XJ Du","year":"2016","unstructured":"Du, X. J. et al. Circulating EBV DNA, globulin and nodal size predict distant metastasis after intensity-modulated Radiotherapy in Stage II nasopharyngeal carcinoma. J. Cancer. 7 (6), 664\u2013670 (2016).","journal-title":"J. Cancer"},{"key":"75396_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2016.12.009","volume":"73","author":"H Liang","year":"2017","unstructured":"Liang, H. et al. Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area. Eur. J. Cancer. 73, 48\u201360 (2017).","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"75396_CR43","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/hed.27011","volume":"44","author":"YT Jiang","year":"2022","unstructured":"Jiang, Y. T. et al. Prognostic significance of wait time for radical radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Head Neck. 44 (5), 1182\u20131191 (2022).","journal-title":"Head Neck"},{"key":"75396_CR44","doi-asserted-by":"crossref","unstructured":"Ying, L. et al. Comorbidity profiling identifies potential subtype of elderly patients with nasopharyngeal carcinoma. Oncologist. 29(8), e1020-e1030 (2024).","DOI":"10.1093\/oncolo\/oyae063"},{"issue":"2","key":"75396_CR45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.21147\/j.issn.1000-9604.2023.02.04","volume":"35","author":"Z Zhan","year":"2023","unstructured":"Zhan, Z. et al. Integrated strategies for chemotherapy cycles in nasopharyngeal carcinoma patients: real-world data from two epidemic centers guiding decision-making. Chin. J. Cancer Res. 35 (2), 126\u2013139 (2023).","journal-title":"Chin. J. Cancer Res."},{"issue":"4","key":"75396_CR46","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","volume":"21","author":"JC Lin","year":"2003","unstructured":"Lin, J. C. et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J. Clin. Oncol. 21 (4), 631\u2013637 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"75396_CR47","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1200\/JCO.2022.40.16_suppl.6068","volume":"40","author":"QY Chen","year":"2022","unstructured":"Chen, Q. Y. et al. Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a single-arm, phase II trial. J. Clin. Oncol. 40 (16), 6068\u20136068 (2022).","journal-title":"J. Clin. Oncol."},{"key":"75396_CR48","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial. Ann. Oncol. 34, S581 (2023).","DOI":"10.1016\/j.annonc.2023.09.2064"},{"issue":"16","key":"75396_CR49","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.1200\/JCO.2023.41.16_suppl.6010","volume":"41","author":"EP Hui","year":"2023","unstructured":"Hui, E. P. et al. NEOSPACE trial: Neoadjuvant pembrolizumab- gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC). J. Clin. Oncol. 41 (16), 6010\u20136010 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"10445","key":"75396_CR50","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 403 (10445), 2720\u20132731 (2024).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75396-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T12:08:00Z","timestamp":1729253280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75396-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75396"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75396-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24484"}}